RecruitingNCT04968834

Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy


Sponsor

Dana-Farber Cancer Institute

Enrollment

300 participants

Start Date

Jun 11, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.


Eligibility

Max Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood and bone marrow samples from children and young adults with blood cancers (such as leukemia or myelodysplastic syndrome) to create a research bank for genomic (gene-level) profiling. The goal is to better understand these cancers and improve future treatments. **You may be eligible if...** - You are from birth up to 29 years old - You have been diagnosed with a blood cancer such as acute or chronic leukemia, MDS (a bone marrow disorder), or a related myeloproliferative condition — either newly diagnosed or relapsed/returned - Your diagnosis has been confirmed by standard pathology testing - Adequate tissue or blood samples are available (or can be collected during planned clinical procedures) **You may NOT be eligible if...** - There is not enough cancer tissue or blood available for testing - Your diagnosis or recurrence cannot be confirmed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICGenomic profiling

Genomic profiling using CLIA assay


Locations(8)

Connecticut Children's Medical Center

Hartford, Connecticut, United States

Maine Medical Center

Portland, Maine, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Dartmouth-Hitchcock

Lebanon, New Hampshire, United States

Albany Medical Center

Albany, New York, United States

Lifespan Cancer Institute

Providence, Rhode Island, United States

University of Vermont Medical Center

Burlington, Vermont, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04968834


Related Trials